Gain an overview on the most relevant biochemical biophysics/ label-free technologies for screening and lead finding. Learn judging how this quite novel technologies toolbox helps drug discovery projects.
Focus: biophysics assay applications that allow the detection, quantification and qualification of ligand/protein binding events with suitability for screening and hit follow-up.
Learn the strategies of the technologies, key applications in drug discovery projects and usage regarding impact and limitations.
Dr. Christine Genick has been working since 2000 in the field of label free technologies: not only on the development of technologies for screening, but also in the utilization of these approaches for lead finding in drug discovery. In 2009, she joined the Screening Sciences Group at Novartis, as a laboratory head in charge of the biophysical hit validation for HTS and FBS. In conjunction with these responsibilities, she and other members of the group evaluate new applications, novel technologies, and approaches to detect small molecule binding interactions with target proteins.
Dr. Delphine Collin received her Ph.D. in Physical Chemistry with a concentration in NMR and structural biology from University of Paris, France. Her post-doctoral research at the University of California, Berkeley focused on single molecule RNA unfolding using the optical tweezers technology. Dr. Collin spent 5 years at Merck & Co., Inc. in the Department of Automated Biotechnology where she developed an automated biophysics lab. In 2009 Dr Collin joined Boehringer Ingelheim in the Department of Medicinal Chemistry. Her group uses label-free technologies for Fragment base screening, protein characterization as well as hit triaging for medicinal chemistry.